Molecular therapy for renal diseases

American Journal of Kidney Diseases

Volumn 28, Issue 4, 1996, Pages 475-492

  Lipkowitz, Michael S ^a   Klotman, Mary E ^b   Bruggeman, Leslie A ^b   Nicklin, Paul ^b   Hanss, Basil ^b   Rappaport, Jay ^b   Klotman, Paul E ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

adeno associated virus vectors; adenovirus vectors; antisense oligodeoxynucleotides; gene therapy; liposomes; Molecular therapy; renal disease; retrovirus vectors; ribozymes

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; LIPOSOME; RIBOZYME; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; KIDNEY DISEASE; NONHUMAN; PROMOTER REGION; RETROVIRUS; REVIEW; SUBSTITUTION THERAPY; TARGET CELL; TISSUE SPECIFICITY;

EID: 0029837352     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(96)90457-6     Document Type: Review

References (169)

1. US Renal Data System: USRDS Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994
2. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark, K, San Millan JL, Gamble V, Harris PC: The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 10:151-160, 1995
3. The International Polycystic Kidney Disease Consortium. Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. Cell 81:289-298, 1995
4. Tryggvason K, Zhou J, Hostikka SL, Shows TB: Molecular genetics of Alport syndrome. Kidney Int 43:38-44, 1993
5. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR, Ulick S, Milora RV, Findling JW: Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79:407-414, 1994
6. + channel. Cell 83:969-978, 1995
7. Harden PN, Geddes C, Rowe PA, McIlroy JH, Boulton-Jones M, Stuart R, Rodger C, Junor BJR, Briggs JD, Connell JMC, Jardine AG: Polymorphisms in angiotensin-converting enzyme gene and progression of IgA nephropathy. Lancet 345:1540-1542, 1995
8. Yorioka, T, Suehiro T, Yasuoka N, Hashimoto K, Kawada M: Polymorphisms of the angiotensin-converting enzyme gene and clinical aspects of IgA nephropathy. Nephron 44:80-85, 1995
9. Winston JA, Klotman PE: Are we missing an epidemic of HIV-associated nephropathy? Editorial review. J Am Soc Nephrol 7:1-7, 1996
10. Wilson JM: Gene therapy for cystic fibrosis: Challenges and future directions. J Clin Invest 96:2547-2554, 1995
11. Blaese MR, Culver KW, Miller AD, Carter CC, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Toltoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270:475-480, 1995
12. Border WA, Noble NA: Transforming growth factor β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
13. Sharma K, Ziyadeh F: The transforming growth factor-beta system and the kidney. Semin Nephrol 13:116-128, 1993
14. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346:371-374, 1990
15. Border WA, Ruoslahti E: Transforming growth factor-β1 induces extracellular matrix formation in glomerulonephritis. Cell Differ Dev 32:425-432, 1990
16. Coimbra T, Wiggins R, Noh JW, Merritt S, Phan SH: Transforming growth factor-beta production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 138:223-234, 1991
17. Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44:313-321, 1993
18. Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Nagao S, Takahashi H, Koide H: Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol 3:1378-1386, 1993
19. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90:1814-1818, 1993
20. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S: Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 68:154-163, 1993
21. Kopp JB, Klotman PE: Animal models of lentivirus-associated renal disease. Contemp Issues Nephrol 29:381-404, 1995
22. Kopp JB, Ray PE, Adler SA, Bruggeman LA, Mangurian CV, Owens JW, Eckhaus MA, Bryant JA, Klotman PE: Nephropathy in HIV-transgenic mice. Contrib Nephrol 107:194-204, 1994
23. Nakamura T, Miller D, Ruoslahti E, Border WA: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 41:1213-1221, 1992
24. Border WA, Okuda S, Nakamura T, Languino LR, Ruoslahti E: Role of TGF-β1 in experimental glomerulonephritis, in Clinical Applications of TGF-β. London, United Kingdom, Ciba Foundation, 1991, pp 178-193
25. Creely JJ, DiMari SJ, Howe AM, Haralson MA: Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 140:45-55, 1992
26. Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RA: TGF-beta stimulates rat mesangial cell proliferation in culture: Role of PDGF beta-receptor expression. Am J Physiol 264:F199-205, 1993
27. Kopp JB, Klotman ME, Adler SH, Dickie P, Marinos NJ, Bryant JL, Eckhaus M, Owens J, Notkins AL, Klotman PE: Glomerulosclerosis in mice transgenic for HIV-1 genes. Proc Natl Acad Sci U S A 89:1577-1581, 1992
28. Rappaport J, Kopp JB, Klotman PE: Molecular regulation of HIV-1 and host pathogenesis. Kidney Int 46:16-27, 1994
29. Bruggeman LA, Nelson PJ, Kopp JB, Rappaport J, Klotman PE, Klotman ME: Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent. Virology 202:940-948, 1994
30. Schrick JJ, Onuchic LF, Reeders ST, Korenberg J, Chen XN, Moyer JH, Wilkinson JE, Woychik RP: Characterization of a human homologue of the mouse Tg737 candidate polycystic kidney disease gene. Hum Mol Genet 4:559-567, 1995
31. Davisson MT, Guay-Woodford LM, Harris HW, D'Eustachio P: The mouse polycystic kidney disease mutation (cpk) is located on proximal chromosome 12. Genomics 9:778-781, 1991
32. Wicker LS, Todd JA, Peterson LB: Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 13:179-200, 1995
33. Miller AD: Retrovirus vectors. Curr Topics Microbiol Immunol 158:1-24, 1992
34. Bosch RJ, Woolf AS, Fine LG: Gene transfer into mammalian kidney: Direct retrovirus-transduction of regenerating tubular epithelial cells. Exp Nephrol 1:49-54, 1993
35. Woolf AS, Bosch RJ, Fine LG: Gene transfer into mammalian kidney: Microtransplantation of retrovirus transduced metanephric tissue. Exp Nephrol 1:41-48, 1993
36. Koseki C, Herzlinger D, Al-Awqati Q: Integration of embryonic cells carrying a reporter gene into functioning nephrons. Am J Physiol 261:C550-554, 1991
37. Kitamura M, Taylor S, Unwin R, Burton S, Shimizu F, Fine LG: Gene transfer into the rat renal glomerulus via a mesangial cell vector: Site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo. J Clin Invest 94:497-505, 1994
38. Purcell DF, Broscius CM, Vanin EF, Buckler CE, Nienhuis AW, Martin MA: An array of murine leukemiavirus related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol 70:887-897, 1996
39. Moullier P, Friedlander G, Calise D, Ronco P, Perricaudet M, Ferry N: Adenoviral-mediated gene transfer to renal tubule cells in vivo. Kidney Int 45:120-1225M, 1994
40. Zhu G, Nicolson AG, Cowley B, Rosen S, Sukhatme VP: In vivo adenovirus-mediated gene transfer into normal and cystic rat kidneys. Genetherapy 3:298-304, 1996
41. Setoguchi Y, Jaffe HA, Chu CS, Crystal RG: Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 10:369-377, 1994
42. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, Libby P, Dichek DA: Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 96:2955-2965, 1995
43. Berns KI, Bohenzky RA: Adeno-associated viruses: An update. Adv Virus Res 32:243-306, 1987
44. Samulski RJ, Chang LS, Shenk T: Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol 63:3822-3828, 1989
45. Lipkowitz MS, Ross MD, Kurtzman GJ, Klotman PE, Klotman ME: Adeno-associated virus (AAV) gene therapy vectors transduce renal mesangial cells in culture. J Am Soc Nephrol 6:891, 1995 (abstr)
46. Muzycka N: Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158:97-129, 1992
47. Flotte TR, Solow R, Owens RA, Afione S, Zeitlin PL, Carter BJ: Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol 7:349-356, 1992
48. Philip R, Brunette E, Kilinski L, Murugesh D, Mcnally MA, Ucar K, Rosenblatt J, Okarma TB, Lebkowski JS: Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 14:2411-2418, 1994
49. Goodman S, Xiao X, Donahue RE, Moulton A, Miller J, Walsh C, Young NS, Samulski RJ, Nienhuis AW: Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood 84:1492-1500, 1994
50. Zhou SZ, Cooper S, Kang LY, Ruggierri L, Heimfeld S, Srivastava A, Broxmeyer HE: Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 179:1867-1875, 1994
51. Zhou SZ, Broxmeyer HE, Cooper S, Harrington MA, Srivastava A: Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp Hematol 21:928-933, 1993
52. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941-3950, 1991
53. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 87:2211-2215, 1990
54. Rivadeneira ED, Popescu NC, Zimongic D, Ross MD, Cheng GS, DiPaolo JA, Gallo RC, Klotman ME: Recombinant adeno-associated virus for gene delivery: Transduction and integration. AIDS Res Hum Retroviruses 10:S159, 1994
55. Flotte TR, Afione SA, Zeitlin PL: Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 11:517-521, 1994
56. Podsakoff G, Wong KK Jr, Chatterjee S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 68:5656-5666, 1994
57. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Genet 8:148-153, 1994
58. Muzyczka N: Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158:97-129, 1992
59. Alexander IE, Russell DW, Miller AD: DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 68:8282-8287, 1994
60. Russell DW, Alexander IE, Miller AD: DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A 92:5719-5723, 1995
61. Kotin RM: Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 5:793-801, 1994
62. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection, a highly efficient lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84:7413-7417, 1987
63. Zhou X, Huang L: DNA transfection mediated by cationic liposomes containing lipopolylysine: Characterization and mechanism of action. Biochim Biophys Acta 1189:195-203, 1994
64. Nabel GJ, Nabel EG, Yang Z-Y, Fox BA, Plautz GP, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A 90:11307-11311, 1993
65. San H, Yang Z-Y, Pomphill VJ, Jaffe ML, Plautz GE, Xhu L, Feigner JH, Wheeler CJ, Feigner PL, Gao X, Huang L, Gordon D, Nabel GJ, Nabel EJ: Safety and short term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 4:781-788, 1993
66. Nabel EG, Yang Z-Y, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ: Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature 362:844-846, 1993
67. Nabel EG, Yang Z-Y, Liptay S, San H, Gordon D, Haudenschild CC, Nabel GJ: Recombinant platelet-derived growth factor β gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 91:1822-1829, 1993
68. Nabel E , Gordon D, Yang Z-Y, Xhu L, San H, Plautz GE, Wu B-Y, Gao X, Huang L, Nabel GJ: Gene transfer in vivo with DNA-liposome complexes: Lack of autoimmunity and gonadal localization. Hum Gene Ther 3:649-656, 1992
69. Madry H, Bohlender J, Reszka R, Ganten D, Wagner J: Liposome-mediated in vivo gene transfer to rat kidney tubular cells. J Am Soc Nephrol 5:630, 1994 (abstr)
70. Kien YH, Lai L, Moeckel GW, Xu H, Martin D, Erickson RP: Liposome-mediated gene transfer targeted to the kidney in mice: Comparison among intra-renal-arterial (IA), retrograde-intrapelvic (IP), and intra-renal-parenchymal (IK) injections. J Am Soc Nephrol 5:629, 1994 (abstr)
71. Tomita N, Higaki J, Morishita R, Kato K, Mikami H, Kaneda Y, Ogihara T: Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 186:129-134, 1992
72. Isaka I, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E: Glomerulosclerosis induced by in vivo transfection by transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92:2597-2601, 1993
73. Akami T, Arkawa K, Okamoto M, Akioka K, Fujiwara I, Nakai I, Mitsuo M, Tomita N, Kaneda Y, Tanaka K, Oka T: Introduction and expression of human CD59 gene in the canine kidney. Transplant Proc 26:1315-1317, 1994
74. Tomita N, Kim J, Gibbons GH, Baran D, Ogborn M, Stahl RAK, Tomita S, Zhang L, Kaneda Y, Dzau VJ: In vivo gene therapy of anti-thy 1 nephritis using e2f decoy oligonucleotide. J Am Soc Nephrol 6:887, 1995 (abstr)
75. Stewart MJ, Plautz GE, DelBuono L, Yang Z-Y, Xu L, Gao X, Huang L, Nabel EG, Nabel GJ: Gene transfer in vivo with DNA-liposome complexes: Safety and acute toxicity in mice. Hum Gene Ther 3:267-275, 1992
76. Setoguchi Y, Jaffe HA, Chu CS, Crystal RG: Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 10:369-377, 1994
77. Lee K-D, Hong K, Papahadjopoulos D: Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta 1103:185-197, 1992
78. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA: Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23:279-291, 1992
79. Philip R, Brunette E, Kilinski L, Murugesh D, Mcnally MA, Ucar K, Rosenblatt J, Okarma TB, Lebkowski JS: Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol Cell Biol 14:2411-2418, 1994
80. Vieweg J, Boczowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C, Gilboa E: Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55:2366-2372, 1995
81. Schelling AN, Smith MG: Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. Gene Ther 1:165-169, 1994
82. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA: Decorin gene therapy for experimental glomerulonephritis. J Am Soc Nephrol 6:897, 1995 (abstr)
83. Kashihara N, Maeshima Y, Sekikawa T, Okamoto K, Kanao K, Sugiyama H, Makino H, Ota Z, Yasuda T: Inhibition of human mesangial cell proliferation by decoy oligonucleotide targeting the transcription factor NF-κB. J Am Soc Nephrol 6:834, 1995 (abstr)
84. Beale EG, Clouthier DE, Hammer RE: Cell-specific expression of cytosolic phosphoenolpyruvate carboxykinase in transgenic mice. FASEB J 6:3330-3337, 1992
85. Patel YM, Yun JS, Liu J, McGrane MM, Hanson RW: An analysis of regulatory elements in the phosphoenolpyruvate carboxykinase (GTP) gene which are responsible for its tissue-specific expression and metabolic control in transgenic mice. J Biol Chem 269:5619-5628, 1994
86. Vicart P, Schwartz B, Vandewalle A, Bens M, Delouis C, Panthier J-J, Pournin S, Babinet C, Paulin D: Immortalization of multiple cell types in transgenic mice using a transgene containing the vimentin promoter and a conditional oncogene. Exp Cell Res 214:35-45, 1994
87. Ercolani L, Florence B, Denaro M, Alexander M: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 263:15335-15341, 1988
88. Nakajima T, Tsunoda S, Nakada S, Nagata S, Oda K: Hyperproduction of human interferon γ by rat cells maintained in low serum medium using the fibronectin gene promoter. J Biochem Tokyo 112:590-597, 1992
89. Sepulveda AR, Carter BZ, Habib GM, Lebovitz RM, Lieberman MW: The mouse gamma-glutamyl transpeptidase gene is transcribed from at least five separate promoters. J Biol Chem 269:10699-10705, 1994
90. Price PM, Megyesi J, Saggi S, Saferstein RL: Regulation of transcription by the rat epidermal growth factor gene promoter in normal and ischemic murine kidney cells. Am J Physiol 268:F664-670, 1995
91. Catanzaro DF, Sun J, Gilbert MT, Yan Y, Black T, Sigmund C, Gross KW: A Pit-1 binding site in the human renin gene promoter stimulates activity in pituitary, placental and juxtaglomerular cells. Kidney Int 46:1513-1515, 1994
92. Witzgall R, O'Leary E, Gessner R, Ouellette AJ, Bonventre JV: Kid-1, a putative renal transcription factor: Regulation during ontogeny and in response to ischemia and toxic injury. Mol Cell Biol 13:1933-1942, 1993
93. Fukamizu A, Watanabe M, Inoue Y, Kon Y, Shimada S, Shiota N, Sugiyama F, Murakami K: Cortical expression of the human angiotensinogen gene in the kidney of transgenic mice. Kidney Int 46:1533-1535, 1994
94. Blaurock, MC, Reboucas NA, Kusnezov JL, Igarashi P: Phylogenetically conserved sequences in the promoter of the rabbit sodium-hydrogen exchanger isoform 1 gene (NHE1/SLC9A1). Biochim Biophys Acta 1262:159-163, 1995
95. Takeaka M, Bagnasco SM, Preston AS, Uchida S, Yamauchi A, Kwon HM, Handler JS: The canine betaine γ-amino-n-butyric acid transporter gene: Diverse mRNA isoforms are regulated by hypertonicity and are expressed in a tissue specific manner. Proc Natl Acad Sci U S A 92:1072-1076, 1995
96. Ponder KP, Dunbar RP, Wilson DR, Darlington GJ, Woo SL: Evaluation of relative promoter strength in primary hepatocytes using optimized lipofection. Hum Gene Ther 2:41-52, 1991
97. Hafenrichter DG, Ponder KP, Rettinger SD, Kennedy SC, Wu X, Saylors RS, Flye MW: Liver-directed gene therapy: Evaluation of liver specific promoter elements. J Surg Res 56:510-517, 1994
98. Hafenrichter DG, Wu X, Rettinger SD, Kennedy SC, Flye MW, Ponder KP: Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 84:3394-3404, 1994
99. Stein CA, Cheng YC: Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004-1012, 1993
100. Wakita T, Wands JR: Specific inhibition of hepatitis C virus expression by antisense oligonucleotides. J Biol Chem 269:14205-14210, 1994
101. Tung FYT: Suppression of SIV replication in primary peripheral mononuclear cells by antisense RNA. J Med Virol 42:255-258, 1994
102. Roth G, Curiel T, Lacy J: Epstein-Barr viral nuclear antigen 1 antisense oligonucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84:582-587, 1994
103. Goodchild J, Agrawal S, Civeira M, Sarin PS, Sun D, Zamecnik PC: Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 85:5507-5511, 1988
104. Li G, Lisziewicz J, Sun D, Son G, Daefler S, Wong-Staal F, Gallo RC, Klotman ME: Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. J Virol 67:6882-6888, 1993
105. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R: Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: A model of treatment. Proc Natl Acad Sci U S A 89:11209-11213, 1992
106. Matsukura M, Zon G, Shinozuka K, Robert-Guroff M, Shimable T, Stein CA, Mitsuya H, Wong-Staal F, Cohen JS, Broder S: Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against Rev (art/trs) in chronically infected cells. Proc Natl Acad Sci U S A 86:4244-4248, 1989
107. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R: Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A 90:9901-9905, 1993
108. Campos L, Sabido O, Rouault J, Guyatat D: Effects of BCL-2 antisense oligonucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595-600, 1994
109. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R: Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218-2222, 1994
110. Rossi G, Pan Y, Cheng J, Pasternak GW: Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the Mu receptor. Life Sci 54:375-379, 1994
111. Sakai RR, He PF, Yang XD, Ma LY, Guo YF, Reilly JJ, Moga CN, Fluharty SJ: Intracerebroventricular administration of AT-1 receptor antisense oligonucleotide inhibits the behavioral actions of angiotensin II. J Neurochem 62:2053-2056, 1994
112. Standifer KM, Chier C, Wahlestadt C, Brown GP, Pasternak GW: Selective loss of Mu opioid analgesia and binding by antisense oligodeoxynucleotides to Mu opioid receptor. Neuron 12:805-810, 1994
113. Tseng LF, Collins KA: Antisense oligonucleotides to a Mu opioid receptor given intrathecally blocks ICV administered β endorphin-induced antinociception in mouse. Life Sci 55:127-131, 1994
114. McCarthy MM, Kleopoulos SP, Mobbs CV, Pfaff DW: Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen-induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology 59:432-440, 1994
115. Simons M, Edelman ER, DeKeyser J, Langer R, Rosenberg RD: Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 359:67-70, 1992
116. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gerwirtz AM: In vivo treatment of human leukemia in a seid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 89:11823-11827, 1992
117. Offensperger W, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, Gerok W: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate antisense oligodeoxynucleotides. EMBO J 12:1257-1262, 1993
118. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4:201-206, 1994
119. Zhao Q, Matson S, Herrera CJ, Fisher E, Yu H, Kreig AM: Comparison of cellular binding and uptake of antisense phosphorodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 3:53-66, 1993
120. Mojcik CF, Gourley MF, Klinman DM, Krieg AM, Gmelig-Meyling F, Steinberg AD: Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immun Immunopath 67: 130-136, 1993
121. Archambault D, Stein CA, Cohen JS: Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses. Arch Virol 139:97-109, 1994
122. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 88:7595-7599, 1991
123. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharm Exp Ther 267:1181-1190, 1993
124. Goodarzi G, Watabe M, Watabe K: Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm Drug Dispos 13:221-227, 1992
125. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE: Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int 47:1462-1469, 1995
126. Wu-Pong S, Weiss TL, Hunt CA: Antisense c-myc oligodeoxynucleotide cellular uptake. Pharm Res 9:1010-1017, 1992
127. Iversen PL, Zhu S, Meyer A, Zon G: Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 2:221-222, 1992
128. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A 86:3474-3478, 1989
129. Bennett FC, Condon TP, Grimm S, Chan H, Chiang M: Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol 152:3530-3540, 1994
130. Chan TM, Frampton G, Cameron JS: Identification of DNA-binding proteins on human umbilical vein endothelial cell plasma membrane. Clin Exp Immunol 91:110-114, 1993
131. Stein CA, Tonkinson JL, Zang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA: Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32:4855-4861, 1993
132. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EI, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci U S A 86:6454-6458, 1989
133. Stein CA, Tonkinson JL, Li-Ming Z, Yakubov L, Gervasoni J, Taub R, Rotenberg SA: Dynamics of internalization of phosphodiester oligonucleotides in HL60 cells. Biochemistry 32:4855-4861, 1993
134. Wu-Pong S, Weiss TL, Hunt CA: Calcium dependent cellular uptake of a c-myc antisense oligonucleotide. Cell Mol Biol 40:843-850, 1994
135. Geselowitz DA, Neckers LM: Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev 2:17-25, 1992
136. Hanss B, Leal-Pinto E, Klotman PE: Antisense oligonucleotide binding protein from proximal tubule brush border membrane functions as an oligonucleotide channel in lipid bilayers. J Am Soc Nephrol 6:362, 1995 (abstr)
137. Boulanger P, Letellier L: Ion channels are likely to be involved in the two steps of phage T5 DNA penetration into Escherichia coli cells. J Biol Chem 267:3168-3172, 1992
138. Guihard G, Boulanger P, Letellier L: Involvement of phage T5 proteins and contact sites between the outer and inner membrane of Escherichia coli in phage T5 DNA injection. J Biol Chem 267:3173-3178, 1992
139. Simon SM, Blobel G: A protein-conducting channel in the endoplasmic reticulum. Cell 65:371-380, 1991
140. Simon SM, Blobel G: Signal peptides open protein-conducting channels in E. coli. Cell 69:677-684, 1992
141. Chrisey L, Rossi J, Sarver N: Meeting report. Ribozymes: Progress and prospects of catalytic RNA as therapeutic agents. Antisense Res Dev 1:57-63, 1991
142. Rossi JJ, Sarver N: Catalytic antisense RNA (ribozymes): Their potential and use as anti-HIV-1 therapeutic agents. Adv Exp Med Biol 312:95-109, 1992
143. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S: The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 35:849-857, 1983
144. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR: Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31:147-157, 1982
145. Peebles CL, Perlman PS, Mecklenburg KL, Petrillo ML, Tabor JH, Jarrell KA, Cheng H-L: A self-splicing RNA excises an intron lariat. Cell 44:213-223, 1986
146. Forster AC, Symons RH: Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49:211-220, 1987
147. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334:585-591, 1988
148. Hampel A, Tritz R, Hicks M, Cruz P: 'Hairpin' catalytic RNA model: Evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res 18:299-304, 1994
149. Anderson P, Monforte J, Tritz R, Nesbitt S, Hearst J, Hampel A: Mutagenesis of the hairpin ribozyme. Nucleic Acids Res 22:1096-1100, 1994
150. Puttaraju M, Perrotta AT, Been MD: A circular trans-acting hepatitis delta virus ribozyme. Nucleic Acids Res 21:4253-4258, 1993
151. Perrotta AT, Been MD: A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350:434-436, 1991
152. Branch AD, Robertson HD: Efficient trans cleavage and a common structural motif for the ribozymes off the human hepatitis delta agent. Proc Natl Acad Sci U S A 88:10163-10167, 1991
153. Branch AD, Levine BJ, Polaskova JA: An RNA tertiary structure of the hepatitis delta agent contains UV-sensitive bases U-712 and U-865 and can form a bimolecular complex. Nucleic Acids Res 23:491-499, 1995
154. Bertrand E, Rossi JJ: Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonuclear protein A1. EMBO J 13:2904-2912, 1994
155. Herschlag D, Khosla M, Tsuchihashi Z, Karpel RL: An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis. EMBO J 13:2913-2924, 1994
156. Moelling K, Mueller G, Dannull J, Reuss C, Beimling P, Bartz C, Wiedenmann B, Yoon K, Surovoy A, Jung G: Stimulation of Ki-ras ribozynie activity by RNA binding protein, NCp7, in vitro and in pancreatic tumor cell line, capan 1. Ann N Y Acad Sci 15:113-121, 1994
157. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J: Inhibition of human immunodeficiency virus-1 (HIV-1) expression by a hairpin ribozyme. Proc Natl Acad Sci U S A 89:10802-10806, 1992
158. Yu M, Ojwang JO, Yamada O, Hampel A, Rappaport J, Looney D, Wong-Staal F: A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Nat Acad Sci U S A 90:6340-6344, 1993
159. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi J: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225, 1990
160. Sun LQ, Pyati J, Smythe J, Wang L, Macpherson J, Gerlach W, Symonds G: Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA 92:7272-7276, 1995
161. Zhou C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn EB: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149:33-39, 1994
162. Ohta Y, Tone T, Shitara T, Funato T, Jiao L, Kashfian BI, Yoshida E, Horng M, Tsai P, Lauterbach K, Kashani-Sabet M, Florenes VA, Fodstad O, Scanlon KJ: H-ras ribozyme-mediated alteration of the human melanoma phenotype. Ann N Y Acad Sci 716:242-253, 1994
163. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ: Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 54:900-902, 1994
164. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55:2024-2028, 1995
165. Cai DW, Mukhopadhyay T, Roth JA: Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 2:199-205, 1995
166. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the BCRABL oncogene transcript: In vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 8:3183-3288, 1993
167. Kobayashi H, Dorai T, Holland JF, Ohnuma T: Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 54:1271-1275, 1994
168. Holm PS, Scanlon KJ, Dietel M: Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 70:239-243, 1994
169. Mahieu M, Deschuyteneer R, Forget D, Vandenbussche P, Content J: Construction of a ribozyme directed against human interleukin-6 mRNA: Evaluation of its catalytic activity in vitro and in vivo. Blood 84:3758-3765, 1994